Is current treatment increasing asthma mortality and morbidity?
Mortality and hospital admission rates for asthma have increased in most developed countries over the last 30 years. Many of these countries experienced an epidemic of deaths from asthma in the mid 1960s'-3 and a further epidemic of deaths has been reported more recently in New Zealand. 4 Hospital admissions have climbed rapidly in many countries since-the mid 1960s, especially in children.' Associated with these trends has been a substantial increase in sales of asthma drugs.9 These changes have occurred against the background of an apparent improvement in the treatment ofasthma,'0 the development ofnew drugs," better formulations and delivery systems,'2 and increased understanding of the pharmacokinetics of the drugs used'3 and of the pathogenesis of asthma. '4 The paradox of improving treatment with increasing mortality and morbidity raises the possibility that changes in the prevalence and severity of the illness have occurred and leads to questions about the overall effectiveness of current management of asthma.
The cause of the epidemic of deaths from asthma seen in the mid 1960s in many countries was probably related to the introduction of a higher concentration isoprenaline inhaler,'5 although this is still the subject of debate.3 '6 In 1982 a further epidemic of asthma deaths in New Zealand was reported. 4 Since then an increase in asthma mortality has been reported in England and Wales,'7 Canada,'8 and the United States.'9 The changes in asthma mortality appear to be real and are not easily explained by changes in coding or death certification.' 7 18 20 Possible explanations include a change in prevalence or severity of the disease and a change in case fatality.
The increase in hospital admissions for asthma have been studied extensively, particularly in children.2' In the last 15 There have been many studies of asthma prevalence in different countries and at different times, though the widely varying methods used make comparisons between different times or countries difficult. The diagnosis of asthma has been based on questionnaires, examination, lung function tests, bronchial challenge tests, or various combinations of these. In Birmingham "asthma prevalence" increased from 1 8% in 195727 to 6 3% in 197528; the change may in part at least reflect the change in questions asked in the two studies. In Lower Hutt, New Zealand, there was an increase in prevalence from 7-1 % in 1969 to 13-5% in 1982 in the same two intermediate schools on the basis of answers to the same question-"Has this child suffered from asthma?"'30 Although these data suggest an increase in the prevalence of asthma, they may represent an improvement in disease labelling rather than a true change in the prevalence ofasthma. The appearance of asthma in developing countries, well documented in Papua New Guinea (0-15% in 19723' to 7-3% in 198032)
is highly suggestive of an increase in asthma prevalence. A general practitioner survey found an increase ofabout 80% in people consulting for asthma and hay fever" and, although again this could 82 represent improved disease labelling, it could also reflect some increase in asthma prevalence. Even if asthma prevalence has doubled, however, it does not readily explain the substantial increase in admission rates.
The factors causing such a change are unknown. Known airborne allergens or pollution are unlikely to be responsible,34 although new, unrecognised factors cannot be excluded. The difference in asthma prevalence between developed and developing countries has suggested that differences in dietary sodium may play a part. A positive correlation between table salt purchases and asthma mortality in both men and children, but not in women, was seen in regional data
The evidence suggests that any changes in the prevalence of asthma have been relatively small, yet there has been a dramatic increase in the number of patients with severe episodes requiring hospital admission and a further increase in asthma mortality, particularly in adults. What might be causing these changes?
Evidence of overreliance on sympathomimetic treatment has been seen in studies of both the epidemics of asthma deaths; such overreliance may have resulted in delays before more appropriate treatment was started and therefore indirectly increased the risk of death.3738 Mortality reviews have disclosed errors in management and failure to recognise the severity of the episode by the patients, their families, and their medical practitioners. Similarly, overreliance on beta agonists and failure in medical management may be factors in hospital admissions. It seems unlikely, however, that management of asthma is now worse than a decade ago or that this deterioration occurred simultaneously in several countries.
The correlation between increasing morbidity from asthma and sales of asthma drugs539 raises the possibility of a causal relation. Undoubtedly inhaled beta agonists have a beneficial effect in the treatment of acute asthmatic episodes. But could inhaled beta agonists given regularly make asthma worse or more "brittle" in the long term? Tolerance to the bronchodilating action of beta agonists (tachyphylaxis) has been shown to occur in vitro and in vivo in animals and man in several studies.31' Tachyphylaxis could lead to a worsening of the asthma in patients using beta agonists, though this hypothesis is not supported by most of the clinical data. 42 Another earlier hypothesis was that beta agonists might produce fatal arrhythmias. This subject has been recently reviewed. 43 Animal studies indicate that high doses of beta agonists can produce arrhythmias and myocardial necrosis. The evidence for similar effects in man is scanty. When selective beta agonists are used intravenously arrhythmias are rarely a problem in children or young adults. When these drugs are inhaled only small amounts of the drug reaches the systemic circulation, so arrhythmias would be expected to be less of a problem. If, however, fatal arrhythmias were produced very occasionally by inhaled beta agonists, then changes in the use of these drugs could result in changes in mortality, though such an effect would not be detected in a prospective study unless it was extremely large. The introduction of and overreliance on nebuliser treatment have been implicated," but this could account for at most 8% of the deaths seen in New Zealand. 45 Recently it has been suggested that beta agonists combined with oral theophylline have an additive effect, which at high doses may induce cardiac arrest,' but no evidence for this was found in a detailed study. 38 Could drug induced changes in bronchial hyperresponsiveness be responsible for the increase in asthma mortality and morbidity? The degree of bronchial hyperresponsiveness can be measured by using inhalation tests with agonists such as histamine47 and methacholine. The degree of hyperresponsiveness correlates well with severity of asthma, although there is a considerable range of asthma severity for any level of hyperresponsiveness.48 Three recent studies have shown that regular long term inhaled beta agonists produce an increase in bronchial hyperresponsiveness within 24 The changes in decreased protection or increased bronchial hyperresponsiveness after long term treatment with inhaled beta agonists may be of little consequence for the individual patient and may be undetectable in view of the natural variability in severity seen in asthma. When this deterioration in bronchial hyperresponsiveness is applied to the whole population of patients with asthma the change is potentially of major significance. This is illustrated by the figure, which shows the frequency distribution of asthma severity as measured by the cumulative dose of histamine that causes a 20% fall in FEV, (PD20). A very small change in bronchial hyperresponsiveness in the population results in a small increase in the number of patients with moderate asthma but a substantial increase in the proportion ofpatients in the severe category.
Whether or not this change in bronchial hyperresponsiveness is important can be resolved only by a large clinical trial in which asthmatic patients are randomised into groups receiving either beta agonists for regular inhalation or beta agonists to be inhaled sparingly. Earlier studies found slightly better peak flow and FEV, values in patients taking regular beta agonists, 57 and led to the recommendation that the first line of treatment for the ambulatory patient is regular inhaled beta agonists.'3 The sample size in these studies has been too small, however, to detect any long term benefit or disadvantage of regular inhaled beta agonists, such as a change in the number of severe asthmatic episodes and admissions to hospital. Until such a study has been reported it seems prudent to avoid using regular high doses of inhaled 83 beta agonists and to reserve these for symptomatic treatment 
